-

Posts Tagged ‘antiretroviral therapy’

RSS

February 17th, 2013

An Adherence Intervention That Works — But There’s a Catch

In a previous post, we reviewed the various flavors of medication non-adherence, and concluded with this tantalizing line: Next up:  An Adherence Intervention that Actually Works — But There’s a Catch Well here it is, just published online in JAMA Internal Medicine. Dr. Robert Gross (a long-time HIV adherence researcher from U Penn) and colleagues […]


February 13th, 2013

Medication Adherence: The Final Frontier

Treatment of HIV has become so amazingly effective that when it fails, it’s no overstatement to say that it’s usually because the patient is not taking the medications.  There are all kinds of provider-related reasons for this — inadequate patient education, prescribing and dispensing errors, failure to address language or education deficits — but here […]


November 18th, 2012

The 800-mg Darunavir Tablet Arrives, and Scoring the Top Protease Inhibitors

The FDA has approved an 800-mg tablet of darunavir for treatment naive patients. This single tablet will obviously replace the two darunavir 400-mg tablets in first-line therapy. (Yes, my math is that good.) Darunavir will still require 100-mg ritonavir boosting plus two NRTIs to make a complete regimen. Once upon a time I might have thought this […]


October 22nd, 2012

Can a “Treat Everyone with HIV” Policy Actually Work? In San Francisco, Yes

As has often been the case in the history of the HIV epidemic, the HIV/AIDS Division at San Francisco General Hospital and the San Francisco Department of Health were ahead of the curve in 2010 when they issued a recommendation that all people with HIV should receive treatment, regardless of CD4 count. Of course, US guidelines […]


July 1st, 2012

“HAART Era” Now Longer Than “Pre-HAART Era” — Can We Officially Retire “HAART”?

As I’ve shared before, I’m no fan of the term “HAART” and do everything I can to stop people from using it. (I’m a fun guy to have at parties.) I’m returning to this pet peeve of mine because I realized recently that we’ve passed a milestone of sorts: Period of no effective HIV treatment, […]


June 20th, 2012

Abacavir Becomes the Latest Generic Antiretroviral Agent

Hot on the heels of generic nevirapine comes generic abacavir: On June 18, 2012, FDA granted approval for a generic formulation of abacavir tablets, 300 mg, manufactured by Mylan Pharmaceuticals, indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. FDA has determined that the generic formulation is bioequivalent and, therefore, therapeutically equivalent to […]


January 8th, 2012

Journal Club: In Early HIV Infection, Little Reason to Delay Therapy

Every experienced HIV clinician will recognize the following new-patient scenario: At least one, but often several negative HIV antibody tests in the past, generally due to being in a “high risk” group. Recent non-specific viral-type illness that, in hindsight, was undoubtedly acute HIV infection, undiagnosed. Now completely recovered, but found to be newly HIV antibody […]


October 29th, 2011

Will An Antiretroviral Patch Help Adherence? Doubtful …

This little nugget came up recently, found by our Journal Watch Executive Editor: Preliminary research suggests that a patch could deliver an AIDS drug to patients … The researchers successfully used transdermal patches to administer 96 percent of an AIDS drug to simulated skin over a week. “Still, the important limitation of pills, regardless of how […]


October 23rd, 2011

TB, Timing of Antiretroviral Therapy, and Being a Lumper Rather Than a Splitter

Three key papers on timing of ART in patients with TB have just been published in the New England Journal of Medicine. Fortunately, Carlos Del Rio has done a bang-up job summarizing them in Journal Watch AIDS Clinical Care. And if you’re wondering how we got our title for Carlos’ piece, here’s an e-mail between our Executive Editor […]


October 19th, 2011

Going, Going, Gone … HIV Treatment Failure Is Disappearing in People Who Take Their Meds

World Series time, hence the baseball reference in the title. (Doesn’t take much.) But over in Lancet Infectious Diseases — which has turned out to be a terrific journal, by the way — there’s a study reminding us that advances in HIV treatment in the late 2000s were truly spectacular. The goal of the paper […]


HIV Information: Author Paul Sax, M.D.

Paul E. Sax, MD

Contributing Editor

NEJM Journal Watch
Infectious Diseases

Biography | Disclosures | Summaries

Learn more about HIV and ID Observations.